Obesity最新文献

筛选
英文 中文
Beyond weight loss: exploring bile acid modulations after bariatric surgery and their impact on type 2 diabetes across 5 years 在减肥之外:探索5年减肥手术后胆汁酸调节及其对2型糖尿病的影响。
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-15 DOI: 10.1002/oby.24308
John Zhiyong Yang, Michelle Li, Weiyu Zhou, Reza Nemati, Xiaodong Jin, Lindsay D. Plank, Rinki Murphy, Jun Lu
{"title":"Beyond weight loss: exploring bile acid modulations after bariatric surgery and their impact on type 2 diabetes across 5 years","authors":"John Zhiyong Yang,&nbsp;Michelle Li,&nbsp;Weiyu Zhou,&nbsp;Reza Nemati,&nbsp;Xiaodong Jin,&nbsp;Lindsay D. Plank,&nbsp;Rinki Murphy,&nbsp;Jun Lu","doi":"10.1002/oby.24308","DOIUrl":"10.1002/oby.24308","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore the dynamic role of bile acids (BAs) in metabolic improvements following bariatric surgery, specifically comparing the effects of silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) and laparoscopic sleeve gastrectomy (LSG) on BA composition and clinical parameters over a 5-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of patients with obesity and type 2 diabetes underwent SR-LRYGB or LSG. Principal component analysis was performed to evaluate BAs and clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Despite significant increases in the first year after surgery, BA levels returned to baseline after 5 years. However, principal component analysis revealed that certain BA profiles may contribute to long-term metabolic benefits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although total BA levels return to baseline by 5 years after surgery, specific BA profiles, as identified by principal component analysis from oral glucose tolerance test data, are associated with sustained metabolic improvements. SR-LRYGB is associated with more durable metabolic benefits compared with LSG. However, given the use of the oral glucose tolerance test, which may not fully capture postprandial BA dynamics, further research using mixed-meal tolerance tests is needed to confirm these findings.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1275-1286"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity 替西肽与生活方式改变对超重和肥胖患者的潜在成本效益建模。
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-13 DOI: 10.1002/oby.24310
Meredith M. Hoog, Hong Kan, Kristen A. Deger, Sonja Sorensen, Lisa M. Neff, Jay Patrick Bae, Emily Ruth Hankosky, Madhumita Murphy, Donna Mojdami, Ivan Houisse, Mack S. Harris
{"title":"Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity","authors":"Meredith M. Hoog,&nbsp;Hong Kan,&nbsp;Kristen A. Deger,&nbsp;Sonja Sorensen,&nbsp;Lisa M. Neff,&nbsp;Jay Patrick Bae,&nbsp;Emily Ruth Hankosky,&nbsp;Madhumita Murphy,&nbsp;Donna Mojdami,&nbsp;Ivan Houisse,&nbsp;Mack S. Harris","doi":"10.1002/oby.24310","DOIUrl":"10.1002/oby.24310","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Our objective was to model the potential cost-effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An individual-level discrete event simulation was implemented in Microsoft Excel linking short-term outcomes from the SURMOUNT-1 trial to key obesity-related complications to estimate costs and health benefits of tirzepatide (5-mg, 10-mg, or 15-mg doses) and LSM over a lifetime time horizon. Treatment-related changes in cardiometabolic factors were modeled using data from SURMOUNT-1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality-adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost-effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The model predicted that all doses of tirzepatide represent cost-effective alternatives to LSM for management of overweight and obesity at a willingness-to-pay threshold of $150,000 per QALY.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1297-1308"},"PeriodicalIF":4.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic clearance rate of insulin across the glucose tolerance spectrum by race and ethnicity in youth with obesity 不同种族和民族的青少年肥胖患者葡萄糖耐量谱胰岛素代谢清除率
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-05 DOI: 10.1002/oby.24317
Wonhee Cho, Fida Bacha, Hala Tfayli, SoJung Lee, Sara F. Michaliszyn, Joon Young Kim, Silva Arslanian
{"title":"Metabolic clearance rate of insulin across the glucose tolerance spectrum by race and ethnicity in youth with obesity","authors":"Wonhee Cho,&nbsp;Fida Bacha,&nbsp;Hala Tfayli,&nbsp;SoJung Lee,&nbsp;Sara F. Michaliszyn,&nbsp;Joon Young Kim,&nbsp;Silva Arslanian","doi":"10.1002/oby.24317","DOIUrl":"10.1002/oby.24317","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Despite β-cell failure in youth with dysglycemia (i.e., impaired glucose tolerance [IGT] and type 2 diabetes), fasting insulin (FI) concentrations are elevated. Herein, we examined the following: 1) metabolic clearance rate of insulin (MCRI) in youth with obesity and normal glucose tolerance (NGT) versus those with IGT versus those with type 2 diabetes; 2) racial and ethnic differences in insulin dynamics; and 3) metabolic/adiposity correlates of MCRI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 206 youth underwent assessment of fasting glucose, FI, MCRI and peripheral insulin sensitivity (PIS), first-phase insulin secretion, disposition index, body composition, and abdominal adiposity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In type 2 diabetes versus NGT, MCRI was lower (<i>p</i> &lt; 0.001), and FI was higher (<i>p</i> &lt; 0.001). In Black versus White youth, MCRI was lower (<i>p</i> &lt; 0.001), driven by lower MCRI in youth with dysglycemia (<i>p</i> &lt; 0.001) and not with NGT. MCRI correlated inversely with FI, as well as adiposity measures, and correlated directly with PIS and disposition index. Lower PIS, lower MCRI, and higher first-phase insulin secretion were characteristics of Black versus White youth with dysglycemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Higher FI concentrations in the presence of dysglycemia despite β-cell failure could be explained by decreased MCRI. Racial and ethnic contrast in insulin dynamics differs by glycemic status and is more pronounced in dysglycemia manifested by lower MCRI and heightened first-phase insulin secretion in Black versus White youth.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1365-1374"},"PeriodicalIF":4.2,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Titration and discontinuation of semaglutide for weight management in commercially insured US adults 美国商业保险成人体重管理中西马鲁肽的滴定和停药。
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-04 DOI: 10.1002/oby.24315
Yunwen Xu, Juan J. Carrero, Alexander R. Chang, Lesley A. Inker, Donglan Zhang, Amrita Mukhopadhyay, Saul B. Blecker, Leora I. Horwitz, Morgan E. Grams, Jung-Im Shin
{"title":"Titration and discontinuation of semaglutide for weight management in commercially insured US adults","authors":"Yunwen Xu,&nbsp;Juan J. Carrero,&nbsp;Alexander R. Chang,&nbsp;Lesley A. Inker,&nbsp;Donglan Zhang,&nbsp;Amrita Mukhopadhyay,&nbsp;Saul B. Blecker,&nbsp;Leora I. Horwitz,&nbsp;Morgan E. Grams,&nbsp;Jung-Im Shin","doi":"10.1002/oby.24315","DOIUrl":"10.1002/oby.24315","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study is to examine real-world dose titration patterns of semaglutide for weight management (Wegovy, Novo Nordisk A/S) in US adults and identify characteristics associated with early discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We identified 15,811 commercially insured adults who started semaglutide for weight management (administrated through single-dose prefilled pens) between June 2021 and December 2023. We depicted dose-titration patterns over 5 months and identified factors associated with discontinuation using multivariable Cox regression. Sensitivity analyses examined patterns after supply shortage resolution (after October 2023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most semaglutide users deviated from the recommended monthly dose-escalation schedule within the first 5 months. By the fifth month, nearly one-half (46%) had discontinued the treatment, with similar rates (48%) among those initiating after supply stabilization. Discontinuation was strongly associated with copayment amount, with rates increased from 41% in the lowest quintile ($1–$54 per month) to 51% in the highest quintile ($161–$1460 per month). Higher discontinuation rates were also associated with lower household income and education level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The deviations from the recommended dose-escalation schedule and high discontinuation rate among real-world semaglutide users indicate important challenges in the delivery of evidence-based care. Policy interventions that reduce financial barriers to the persistence of semaglutide are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1243-1248"},"PeriodicalIF":4.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary macronutrient content and energy intake in the mouse: hedonic or homeostatic override? 小鼠的饮食宏量营养素含量和能量摄入:快乐的还是自我平衡的?
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-04 DOI: 10.1002/oby.24312
Stephen J. Simpson, Alistair M. Senior, Samantha M. Solon-Biet, David G. Le Couteur, David Raubenheimer
{"title":"Dietary macronutrient content and energy intake in the mouse: hedonic or homeostatic override?","authors":"Stephen J. Simpson,&nbsp;Alistair M. Senior,&nbsp;Samantha M. Solon-Biet,&nbsp;David G. Le Couteur,&nbsp;David Raubenheimer","doi":"10.1002/oby.24312","DOIUrl":"10.1002/oby.24312","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to reconcile how two landmark mouse studies came to opposite conclusions regarding the relationship between dietary macronutrient composition and energy intake. Hu et al. concluded that dietary fat drives excess energy intake because its hedonic properties override energy homeostasis. Solon-Biet et al. concluded that energy intake increases with dietary fat owing to the dilution of protein and carbohydrates, with compensatory feeding for these nutrients dominating inhibitory feedback from fat.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Nutritional geometry was used to reanalyze data from Solon-Biet et al. and Hu et al.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results from the two studies are strongly concordant. Neither was designed to measure hedonics but, in both studies, the positive associations among dietary fat, food, and energy intakes are as predicted by compensatory feeding for dietary protein and carbohydrates without the need to impute hedonic effects of fat.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Whereas conclusions cannot be drawn from either study regarding the role of hedonics, there is evidence for homeostatic feedback operating in both. We suggest that hedonic and homeostatic mechanisms likely interact, with homeostasis being more influential over the longer term. Therefore, “hedonic diversion” may be a more appropriate concept than “hedonic override” when considering energy consumption in mice and, perhaps, humans.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1322-1333"},"PeriodicalIF":4.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The food insecurity–obesity paradox: a comparison of three obesity measures and sociodemographic disparities in Korean adults 食品不安全-肥胖悖论:韩国成年人中三种肥胖措施和社会人口差异的比较。
IF 4.2 2区 医学
Obesity Pub Date : 2025-06-03 DOI: 10.1002/oby.24311
Sukyoung Jung, Sohyun Park
{"title":"The food insecurity–obesity paradox: a comparison of three obesity measures and sociodemographic disparities in Korean adults","authors":"Sukyoung Jung,&nbsp;Sohyun Park","doi":"10.1002/oby.24311","DOIUrl":"10.1002/oby.24311","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We explored the impact of food insecurity on three different measures of obesity, that is, estimated percentage body fat (PBF), BMI, and waist circumference (WC), and examined the presence of sociodemographic disparities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study used data from the Korea National Health and Nutrition Examination Survey 2019–2021 (<i>n</i> = 12,447, aged ≥30 years). Food insecurity was evaluated using an 18-item modified version of the US Household Food Security Survey Module. Three obesity measures were defined: PBF ≥25% for men or ≥35% for women, BMI ≥25 kg/m<sup>2</sup>, and WC ≥90 cm for men or ≥85 cm for women. Logistic regression models were employed to estimate odds ratio (OR) values with 95% CI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of those measured, 4% of households experienced food insecurity (men 3.7%, women 4.6%). In women, food insecurity was positively associated with PBF-defined obesity (OR: 1.37, 95% CI: 1.03–1.81) but not with BMI- or WC-defined obesity. When analyzed by sociodemographic factors, positive associations between food insecurity and PBF-defined obesity were observed in older women and urban residents but not in their counterparts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Food insecurity seems to have a stronger positive association with PBF than with BMI or WC among Korean women, especially those who are older and reside in urban areas.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1395-1403"},"PeriodicalIF":4.2,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society 支持GLP-1治疗肥胖的营养优先:美国生活方式医学院、美国营养学会、肥胖医学协会和肥胖学会的联合咨询。
IF 4.2 2区 医学
Obesity Pub Date : 2025-05-30 DOI: 10.1002/oby.24336
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa Sannidhi, Fatima Cody Stanford, Emily A. Callahan
{"title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","authors":"Dariush Mozaffarian,&nbsp;Monica Agarwal,&nbsp;Monica Aggarwal,&nbsp;Lydia Alexander,&nbsp;Caroline M. Apovian,&nbsp;Shagun Bindlish,&nbsp;Jonathan Bonnet,&nbsp;W. Scott Butsch,&nbsp;Sandra Christensen,&nbsp;Eugenia Gianos,&nbsp;Mahima Gulati,&nbsp;Alka Gupta,&nbsp;Debbie Horn,&nbsp;Ryan M. Kane,&nbsp;Jasdeep Saluja,&nbsp;Deepa Sannidhi,&nbsp;Fatima Cody Stanford,&nbsp;Emily A. Callahan","doi":"10.1002/oby.24336","DOIUrl":"10.1002/oby.24336","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinar","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 8","pages":"1475-1503"},"PeriodicalIF":4.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24336","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight 肥胖或超重人群饮食行为患者报告结果测量的开发和验证。
IF 4.2 2区 医学
Obesity Pub Date : 2025-05-28 DOI: 10.1002/oby.24299
Donald M. Bushnell, Shirley Fung, Meryl Brod, Carl A. Roberts, Carel W. Le Roux, Oren Steen, Kathryn J. Lucas, Anita M. Hennige, Anastasia Uster
{"title":"Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight","authors":"Donald M. Bushnell,&nbsp;Shirley Fung,&nbsp;Meryl Brod,&nbsp;Carl A. Roberts,&nbsp;Carel W. Le Roux,&nbsp;Oren Steen,&nbsp;Kathryn J. Lucas,&nbsp;Anita M. Hennige,&nbsp;Anastasia Uster","doi":"10.1002/oby.24299","DOIUrl":"10.1002/oby.24299","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to develop a measure of eating behaviors in adults living with obesity or overweight.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on concept-elicitation (<i>n</i> = 53) and cognitive-debriefing (<i>n</i> = 15) studies, a draft eating behavior patient-reported outcome (EB PRO) measure was developed. Its psychometric properties were established using data from a 46-week clinical trial of an investigational antiobesity medication (<i>n</i> = 387).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The final EB PRO comprised 12 items across two domains (i.e., “Desire to Eat” and “Capacity to Resist”; 6 items each) and a Total Eating Behavior score (0–48; higher scores worse). The EB PRO demonstrated good test–retest reliability (intraclass correlation coefficients &gt; 0.7). Confirmatory factor analysis showed a comparative fit index of 0.98 with good internal consistency (Cronbach α &gt; 0.7). The EB PRO generally exhibited moderate-to-large correlations with the Patient Global Impression of Severity questionnaire and Three-Factor Eating Questionnaire and weaker correlation with the 36-Item Short-Form Health Survey version 2 Physical Functioning scale. All EB PRO scores improved from baseline to week 46 (<i>p</i> &lt; 0.0001), demonstrating sensitivity to change with therapy. Clinically meaningful thresholds were defined as eight- and four-point changes in Total Eating Behavior and domain scores, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The EB PRO measure is a promising tool for assessing eating behaviors in people with obesity or overweight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1249-1262"},"PeriodicalIF":4.2,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study 替西肽与中国成人心脏代谢益处的关联:SURMOUNT-CN研究的事后亚组分析
IF 4.2 2区 医学
Obesity Pub Date : 2025-05-28 DOI: 10.1002/oby.24306
Lin Zhao, Hong Chen, Zhifeng Cheng, Hongwei Jiang, Yibing Lu, Jianzhong Xiao, Xinhua Xiao, Yuanyuan Li, Yuan Yuan, Xiaoying Li
{"title":"Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study","authors":"Lin Zhao,&nbsp;Hong Chen,&nbsp;Zhifeng Cheng,&nbsp;Hongwei Jiang,&nbsp;Yibing Lu,&nbsp;Jianzhong Xiao,&nbsp;Xinhua Xiao,&nbsp;Yuanyuan Li,&nbsp;Yuan Yuan,&nbsp;Xiaoying Li","doi":"10.1002/oby.24306","DOIUrl":"10.1002/oby.24306","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to evaluate the association of tirzepatide with body weight, cardiometabolic markers, and metabolic syndrome in Chinese participants achieving normal body mass index (BMI) values by week 52 across baseline BMI subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This post hoc analysis of SURMOUNT-CN assessed the association of tirzepatide with cardiometabolic risk factors in Chinese participants, categorized by Chinese-specific anthropometric cutoffs for BMI and waist circumference. The association of early weight loss (greater or less than median at 12 and 24 weeks) with cardiometabolic markers and metabolic syndrome was evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this post hoc analysis (<i>N</i> = 177; tirzepatide 10 mg, <i>n</i> = 62; tirzepatide 15 mg, <i>n</i> = 57; placebo, <i>n</i> = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers. Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo (<i>p</i> &lt; 0.05). At week 52, 37 participants achieved a normal BMI (18.5–24 kg/m<sup>2</sup>, Chinese criteria), and metabolic syndrome dropped from 21.6% at baseline to 0%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long-term metabolic health outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1287-1296"},"PeriodicalIF":4.2,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncovering covariance patterns across energy balance traits enables the discovery of new obesity-related genes 揭示能量平衡特征的协方差模式有助于发现新的肥胖相关基因。
IF 4.2 2区 医学
Obesity Pub Date : 2025-05-26 DOI: 10.1002/oby.24291
Davorka Gulisija, Agustin Gonzalez-Reymundez, Jenifer I. Fenton, Gustavo de los Campos, Molly S. Bray, Ana I. Vazquez
{"title":"Uncovering covariance patterns across energy balance traits enables the discovery of new obesity-related genes","authors":"Davorka Gulisija,&nbsp;Agustin Gonzalez-Reymundez,&nbsp;Jenifer I. Fenton,&nbsp;Gustavo de los Campos,&nbsp;Molly S. Bray,&nbsp;Ana I. Vazquez","doi":"10.1002/oby.24291","DOIUrl":"10.1002/oby.24291","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Effective solutions to obesity remain elusive, partly owing to its root in a positive energy balance (EB), which stems from the interplay of numerous traits spanning body size and composition, diet, physical activity, and metabolic profile. Nevertheless, EB-contributing traits are typically studied in isolation. We integrate numerous EB-related traits measured in the UK Biobank to uncover the underlying patterns of EB and associated genes in study participants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used sparse factor analysis to integrate traits and performed genome-wide association analyses on the integrated phenotypes to elucidate EB-related genes and metabolic pathways. We performed pleiotropy analyses on candidate single-nucleotide polymorphisms to uncover the genetic basis of EB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified multiple genes and genomic regions associated with EB, including many that have previously not been directly associated with obesity measures (e.g., <i>MIR5591</i>, <i>FNDC3B</i>, <i>ANAPC10</i>, <i>SULT1A1</i>, <i>AXIN1</i>, <i>SKIDA1</i>, <i>ERLIN1</i>, <i>DOCK7</i>), which we validated using an independent subset of the UK Biobank dataset along with data from the Atherosclerosis Risk in Communities cohort. We found that the covariances in EB traits are primarily driven by genome-wide pleiotropic associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We offer new insight into EB patterns and the genetic basis of EB.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1184-1194"},"PeriodicalIF":4.2,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24291","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信